These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29652967)

  • 1. [Pharmacokinetics of posaconazol in the prophylaxis and treatment of invasive fungal infection in immunocompromised children in a pediatric hospital].
    Valenzuela R; García P; Barraza M; Palma J; Catalán P; Santolaya ME; Torres JP; Morales J
    Rev Chilena Infectol; 2018; 35(1):15-21. PubMed ID: 29652967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole in immunocompromised pediatric patients.
    Vicenzi EB; Cesaro S
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):543-553. PubMed ID: 29912581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
    Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
    PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
    Tüfekçi Ö; Yılmaz Bengoa Ş; Demir Yenigürbüz F; Şimşek E; Karapınar TH; İrken G; Ören H
    Turk J Haematol; 2015 Dec; 32(4):329-37. PubMed ID: 25913290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
    Chin A; Pergam SA; Fredricks DN; Hoofnagle AN; Baker KK; Jain R
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate-day dosing of posaconazole tablets in children leads to efficient plasma levels.
    Mesini A; Faraci M; Giardino S; Ricci E; Barco S; Cangemi G; Lanino E; Castagnola E
    Eur J Haematol; 2018 Jul; 101(1):127-128. PubMed ID: 29543346
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of posaconazole in children: Experience in a tertiary pediatric hospital].
    Rosanova MT; Voto C; Mussini MS; Sarkis C; Gómez S; Sberna N; Carnovale S; Caracciolo B; Lede R
    Arch Argent Pediatr; 2018 Jun; 116(3):e451-e454. PubMed ID: 29756722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation.
    Van Daele R; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):539-550. PubMed ID: 32478597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
    Vicenzi EB; Calore E; Decembrino N; Berger M; Perruccio K; Carraro F; Rossin S; Putti MC; Molinaro M; Tridello G; Cesaro S
    Eur J Haematol; 2018 Mar; 100(3):315-322. PubMed ID: 29240266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
    Bryant AM; Slain D; Cumpston A; Craig M
    Int J Antimicrob Agents; 2011 Mar; 37(3):266-9. PubMed ID: 21236645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.
    Petitcollin A; Boglione-Kerrien C; Tron C; Nimubona S; Lalanne S; Lemaitre F; Bellissant E; Verdier MC
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
    Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
    Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
    Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.
    Welch S; Pallotta A; Weber C; Siebenaller C; Cober E; Neuner E
    Mycoses; 2017 Apr; 60(4):241-243. PubMed ID: 27910211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.